Therapeutic potential of dihydronicotinamide riboside (NRH) on obesity and glucose intolerance in mice - PubMed
6 hours ago
- #NAD+ Precursors
- #Obesity Treatment
- #Metabolic Health
- NAD+ is a key metabolic cofactor with implications for metabolic and age-related diseases, spurring interest in NAD+ precursors like vitamin B3s, though current options have limitations.
- Dihydronicotinamide riboside (NRH), a novel NAD+ precursor, was studied for chronic dietary supplementation in mice, involving phenotyping, RNA sequencing, and microbiome analyses.
- NRH at 100 mg/(kg*day) was well-tolerated but had minimal effects in mice on a regular diet; however, it prevented or treated high-fat diet-induced issues such as glucose intolerance and altered lipid metabolism.
- The study highlights NRH's therapeutic potential for obesity and glucose intolerance, with improved hepatic lipid catabolism gene expression and fat redistribution, but notes toxicity at higher doses, requiring further optimization.